Dehydroepiandrosterone and GDF-15 for follow-up of patients with pulmonary arterial hypertension

V. Foris (Graz, Austria), C. Mutgan (Graz, Austria), A. Borenich (Graz, Austria), G. Kovacs (Graz, Austria), P. Douschan (Graz, Austria), T. Sassmannn (Graz, Austria), K. Zeder (Graz, Austria), A. Olschewski (Graz, Austria), G. Kwapiszewska (Graz, Austria), H. Olschewski (Graz, Austria)

Source: Virtual Congress 2021 – All about pulmonary arterial hypertension
Session: All about pulmonary arterial hypertension
Session type: Oral Presentation
Number: 144

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
V. Foris (Graz, Austria), C. Mutgan (Graz, Austria), A. Borenich (Graz, Austria), G. Kovacs (Graz, Austria), P. Douschan (Graz, Austria), T. Sassmannn (Graz, Austria), K. Zeder (Graz, Austria), A. Olschewski (Graz, Austria), G. Kwapiszewska (Graz, Austria), H. Olschewski (Graz, Austria). Dehydroepiandrosterone and GDF-15 for follow-up of patients with pulmonary arterial hypertension. 144

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Exercise pathophysiology in patients with pulmonary arterial hypertension
Source: Annual Congress 2007 - Mechanisms of exercise intolerance in cardiorespiratory disease
Year: 2007


Plasma big-endothelin and hemodynamics in patients with pulmonary arterial hypertension compared to patients with chronic left heart failure with and without pulmonary venous hypertension
Source: Annual Congress 2009 - Pulmonary circulation I
Year: 2009

Apelin improves cardiac output in patients with pulmonary arterial hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015

Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children
Source: Eur Respir J 2011; 37: 70-77
Year: 2011



Evaluation of serum cytokines in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension with hypercholesterolemia
Source: International Congress 2017 – PAH and CTEPH
Year: 2017


Pulmonary rehabilitation in patients with pulmonary arterial hypertension
Source: ERS Course 2017
Year: 2017

Circulating angiopoietins in idiopathic pulmonary arterial hypertension
Source: Annual Congress 2010 - Pulmonary hypertension
Year: 2010


Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil
Source: Eur Respir J 2006; 28: 1195-1203
Year: 2006



Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension
Source: Eur Respir J 2009; 34: 770
Year: 2009


NT-proBNP variation in stable pulmonary arterial hypertension patients.
Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle
Year: 2018


Pulmonary function in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010

Pulmonary arterial hypertension in children
Source: Eur Respir J 2003; 21: 155-176
Year: 2003



Exercise limitation in idiopathic pulmonary arterial hypertension (IPAH): there‘s more to it than just the pulmonary circulation
Source: Eur Respir J 2005; 26: Suppl. 49, 560s
Year: 2005

Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH)
Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Year: 2005


Capillaroscopic findings in patients with pulmonary arterial hypertension
Source: International Congress 2018 – Clinical aspects of pulmonary hypertension
Year: 2018


Arterial stiffness in patients with chronic obstructive pulmonary disease combined with arterial hypertension
Source: Virtual Congress 2020 – Burden and predictive factors for chronic lung diseases and comorbidity
Year: 2020


Screening for pulmonary vascular disease (PVD) in patients with portal hypertension by investigating pulmonary hemodynamics during exercise
Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension
Year: 2017

Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020
Year: 2020



NT-proBNP correlates with RVEF in patients suffering from pulmonary arterial hypertension
Source: Eur Respir J 2004; 24: Suppl. 48, 110s
Year: 2004

6MWD in patients with pulmonary arterial hypertension (PAH)
Source: Eur Respir J 2003; 22: Suppl. 45, 464s
Year: 2003